Oclacitinib
Oclacitinib is a novel JAK inhibitor. Oclacitinib is most potent at inhibiting JAK1 (IC50=10 nM) .
Product Specifications
CAS Number
1208319-26-9
Product Name Alternative
PF-03394197
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Oclacitinib.html
Concentration
10mM
Purity
99.59
Solubility
DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CN([C@H]1CC[C@@H](CC1)CS(NC)(=O)=O)C2=C3C(NC=C3)=NC=N2
Molecular Formula
C15H23N5O2S
Molecular Weight
337.44
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
JAK1; JAK2; JAK3; Tyk2
Citation 01
BioRxiv. 2025 February 21.|Mol Ther Oncol. 2025 Feb 3;33 (1) :200946.|Dev Comp Immunol. 2018 Dec:89:44-53.|Virulence. 2024 Dec;15 (1) :2435372.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
LOC284297 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
BDNF Brain-Derived Neurotrophic Factor Human Recombinant Protein